Trials / Active Not Recruiting
Active Not RecruitingNCT02487693
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The First People's Hospital of Changzhou · Academic / Other
- Sex
- Female
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Detailed description
The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Radiofrequency ablation | Radiofrequency ablation is performed percutaneously under CT/US guidance |
| BIOLOGICAL | Cytokine-induced killer cells | The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2038-06-01
- Completion
- 2040-06-01
- First posted
- 2015-07-01
- Last updated
- 2016-02-23
Source: ClinicalTrials.gov record NCT02487693. Inclusion in this directory is not an endorsement.